The October 2014 issue of the Canadian Adverse Reaction Newsletter, published by the Marketed Health Products Directorate, Health Products and Food Branch, is now available. This newsletter is a quarterly publication of adverse reaction information and provides regular feedback to health professionals on adverse reactions reported in Canada.
In this issue:
- Incretin-based therapies and the risk of pancreatic cancer
- Intravenous methylprednisolone and liver injury
- Sorafenib and osteonecrosis of the jaw
- Summary of advisories
For a complete listing of previous issues, go to http://www.health.gc.ca/carn
